Law360, New York (May 03, 2005, 12:00 AM ET) -- Cephalon, Inc. has dropped its patent infringement suit against Swiss drug maker Sandoz following that drugmaker's decision not to market a generic version of Cephalon's drug Provigil.
According to Cephalon, Sandoz has decided not to challenge Cephalon's patent position on Provigil, a treatment for excessive day-time sleepiness. Instead, Sandoz will wait until 2014 to seek to put out a generic version of the drug, when a patent on one of Provigil's key ingredients is set to expire.
Instead, Sandoz plans to convert its abbreviated new drug...
Cephalon Drops Patent Suit Vs. Sandoz Over Provigil
To view the full article, take a free trial now.
